Trials / Terminated
TerminatedNCT04625153
RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial
RC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- RemeGen Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
To observe the safety and effectivity of a Recombinant Human B Lymphocyte Stimulator Receptor : Immunoglobulin G( IgG ) Fc Fusion Protein for injection (RC18) in patients with relapsing remitting multiple sclerosis, analyze the dose-response relationship and provide a dose basis for follow-up clinical trials.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | RC18 160mg | RC18 160mg is injected subcutaneously once a week for 48 times. |
| BIOLOGICAL | RC18 240mg | RC18 240mg is injected subcutaneously once a week for 48 times. |
Timeline
- Start date
- 2021-05-13
- Primary completion
- 2026-04-03
- Completion
- 2026-04-03
- First posted
- 2020-11-12
- Last updated
- 2026-04-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04625153. Inclusion in this directory is not an endorsement.